Sunmax Biotechnology Past Earnings Performance
Past criteria checks 4/6
Sunmax Biotechnology has been growing earnings at an average annual rate of 36.7%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 24.4% per year. Sunmax Biotechnology's return on equity is 59.7%, and it has net margins of 40.4%.
Key information
36.7%
Earnings growth rate
36.7%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 24.4% |
| Return on equity | 59.7% |
| Net Margin | 40.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Investors Who Bought Sunmax Biotechnology (GTSM:4728) Shares Three Years Ago Are Now Up 166%
Feb 28
Is Sunmax Biotechnology Co., Ltd. (GTSM:4728) The Right Choice For A Smart Dividend Investor?
Feb 02Sunmax Biotechnology Co., Ltd.'s (GTSM:4728) Stock Is Going Strong: Is the Market Following Fundamentals?
Dec 20Is Sunmax Biotechnology's (GTSM:4728) Share Price Gain Of 152% Well Earned?
Nov 24
Revenue & Expenses Breakdown
How Sunmax Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,760 | 712 | 483 | 35 |
| 31 Mar 24 | 1,724 | 674 | 486 | 32 |
| 31 Dec 23 | 1,689 | 626 | 481 | 29 |
| 30 Sep 23 | 1,674 | 582 | 496 | 28 |
| 30 Jun 23 | 1,564 | 535 | 474 | 23 |
| 31 Mar 23 | 1,468 | 529 | 437 | 20 |
| 31 Dec 22 | 1,400 | 534 | 407 | 18 |
| 30 Sep 22 | 1,292 | 506 | 361 | 18 |
| 30 Jun 22 | 1,181 | 410 | 389 | 20 |
| 31 Mar 22 | 1,093 | 316 | 428 | 24 |
| 31 Dec 21 | 1,036 | 246 | 502 | 25 |
| 30 Sep 21 | 1,050 | 251 | 521 | 21 |
| 30 Jun 21 | 991 | 228 | 492 | 17 |
| 31 Mar 21 | 952 | 245 | 451 | 17 |
| 31 Dec 20 | 856 | 238 | 351 | 18 |
| 30 Sep 20 | 714 | 122 | 328 | 17 |
| 30 Jun 20 | 711 | 162 | 305 | 21 |
| 31 Mar 20 | 670 | 134 | 309 | 21 |
| 31 Dec 19 | 594 | 100 | 317 | 23 |
| 30 Sep 19 | 539 | 145 | 266 | 25 |
| 30 Jun 19 | 427 | 99 | 228 | 23 |
| 31 Mar 19 | 347 | 82 | 184 | 24 |
| 31 Dec 18 | 304 | 75 | 158 | 20 |
| 30 Sep 18 | 259 | 50 | 140 | 16 |
| 30 Jun 18 | 229 | 40 | 131 | 16 |
| 31 Mar 18 | 200 | 28 | 123 | 12 |
| 31 Dec 17 | 190 | 17 | 112 | 12 |
| 30 Sep 17 | 189 | 24 | 100 | 14 |
| 30 Jun 17 | 188 | 24 | 87 | 13 |
| 31 Mar 17 | 164 | 2 | 77 | 17 |
| 31 Dec 16 | 156 | 2 | 77 | 20 |
| 30 Sep 16 | 120 | -31 | 81 | 19 |
| 30 Jun 16 | 112 | -45 | 89 | 22 |
| 31 Mar 16 | 114 | -40 | 94 | 20 |
| 31 Dec 15 | 112 | -44 | 94 | 21 |
| 30 Sep 15 | 151 | -17 | 93 | 30 |
| 30 Jun 15 | 151 | 0 | 86 | 28 |
| 31 Mar 15 | 165 | 13 | 79 | 26 |
| 31 Dec 14 | 184 | 20 | 78 | 22 |
| 30 Sep 14 | 177 | 25 | 77 | 10 |
| 30 Jun 14 | 193 | 28 | 79 | 9 |
| 31 Mar 14 | 212 | 41 | 81 | 9 |
| 31 Dec 13 | 213 | 48 | 82 | 11 |
Quality Earnings: 4728 has high quality earnings.
Growing Profit Margin: 4728's current net profit margins (40.4%) are higher than last year (34.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4728's earnings have grown significantly by 36.7% per year over the past 5 years.
Accelerating Growth: 4728's earnings growth over the past year (33.2%) is below its 5-year average (36.7% per year).
Earnings vs Industry: 4728 earnings growth over the past year (33.2%) did not outperform the Biotechs industry 33.2%.
Return on Equity
High ROE: 4728's Return on Equity (59.7%) is considered outstanding.